Plants are a source of food for many animals, and they can produce thousands of chemicals. Some of these compounds affect physiological processes in the vertebrates that consume them, such as endocrine function. Phytoestrogens, the most well studied endocrine-active phytochemicals, directly interact with the hypothalamo-pituitary gonadal axis of the vertebrate endocrine system. Here we present the novel use of a cell-based assay to screen plant extracts for the presence of compounds that have estrogenic biological activity. This assay uses mammalian cells engineered to highly express estrogen receptor beta (ERβ) and that have been transfected with a luciferase gene. Exposure to compounds with estrogenic activity results in the cells producing light. This assay is a reliable and simple way to test for biological estrogenic activity. It has several improvements over transient transfection assays, most notably, ease of use, the stability of the cells, and the sensitivity of the assay.

Download full-text PDF

Source
http://dx.doi.org/10.3791/61005DOI Listing

Publication Analysis

Top Keywords

estrogen receptor
8
compounds estrogenic
8
estrogenic activity
8
assay
5
screening phytoestrogens
4
phytoestrogens cell-based
4
cell-based estrogen
4
receptor reporter
4
reporter assay
4
assay plants
4

Similar Publications

Bisphenol A and its potential mechanism of action for reproductive toxicity.

Toxicology

December 2024

Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Canada; School of Environmental Studies, Queen's University, Kingston, Canada. Electronic address:

Bisphenol A (BPA) is an organic synthetic chemical used worldwide. Billions of pounds of BPA are produced annually through industrial processes to be used in commercial products, making human exposure to BPA ubiquitous. Concerns have been raised due to the potential adverse health effects of BPA, specifically in vulnerable populations, such as pregnant persons and children.

View Article and Find Full Text PDF

Sex-Dependent Efficacy of Sphingosine-1-Phosphate Receptor Agonist FTY720 in Mitigating Huntington's Disease.

Pharmacol Res

December 2024

Translational Neurodegeneration Research and Neuropathology Lab, Department of Clinical Medicine (KlinMed), Medical Faculty, University of Oslo (UiO) and Section of Neuropathology Research, Department of Pathology, Clinics for Laboratory Medicine (KLM), Oslo University Hospital (OUS), Sognsvannsveien 20, N-0372 Oslo, Norway; Institute of Nutritional Medicine (INUM) and Lübeck Institute of Dermatology (LIED), University of Lübeck (UzL) and University Medical Center Schleswig-Holstein (UKSH), Ratzeburger Allee 160, D-23538 Lübeck, Germany; Faculty of Medicine and Life Sciences, University of Latvia, Jelgavas iela 3, LV-1004 Rīga, Latvia; School of Neurobiology, Biochemistry and Biophysics, The Georg S. Wise Faculty of Life Sciences, Tel Aviv University, Ramat Aviv, IL-6997801, Israel. Electronic address:

Huntington's disease (HD) is a debilitating neurodegenerative disorder characterized by severe motor deficits, cognitive decline and psychiatric disturbances. An early and significant morphological hallmark of HD is the activation of astrocytes triggered by mutant huntingtin, leading to the release of inflammatory mediators. Fingolimod (FTY), an FDA-approved sphingosine-1-phosphate (S1P) receptor agonist is used to treat multiple sclerosis (MS), a neuroinflammatory disease, and has shown therapeutic promise in other neurological conditions.

View Article and Find Full Text PDF

Objective: analysis of molecular genetic phenotypes, their proliferative activity, degree of spread and differentiation of tumors in breast cancer patients affected by the accident at the Chornobyl Nuclear Power Plant.

Materials And Methods: 96 breast cancer patients who were exposed to ionizing radiation as a result of the accident at the Chornobyl Nuclear Power Plant were examined. Clinical, radiological, instrumental, morphological,immunohistochemical research methods were used.

View Article and Find Full Text PDF

Aim: We report a case of proliferative myositis (PM) of the breast, which is the second reported in the English literature.

Case Presentation: A 49-year-old woman underwent surgery due to a fibroadenoma in the right and phyllodes tumor in the left breast. One month after these surgeries, a right breast mass rapidly grew at the surgical site, and biopsy did not provide a diagnosis.

View Article and Find Full Text PDF
Article Synopsis
  • Uterine carcinosarcoma (UCS) is a rare cancer combining both carcinoma and sarcoma features, often resembling endometrial carcinoma, with a potential link to nulliparity (never having given birth) as a risk factor.
  • A 55-year-old woman presented with postmenopausal vaginal bleeding and was diagnosed after surgery, revealing well-differentiated adenocarcinoma and osteosarcoma components, along with multiple positive immunohistochemical markers.
  • Following a series of surgical interventions and treatments, including chemotherapy and radiotherapy, the patient demonstrated no signs of tumor recurrence and had a disease-free survival of seven months as of July 2024.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!